INCONTROL: The Effects of RT-CGM on Glycemia and QoL in Patients With T1DM and IHA
Study Details
Study Description
Brief Summary
The purpose of this study is to determine what the effects are of real-time continuous glucose monitoring on glycemia and quality of life in patients with type 1 diabetes mellitus and impaired hypoglycemia awareness.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
The investigators hypothesize that the use of RT-CGM, relative to a control intervention using masked CGM, will result in improvement of various measures of glycemia and indicators of quality of life, reduce the occurrence of hypoglycemia and hyperglycemia and restore hypoglycemia awareness in T1DM patients with IHA. We will test this hypothesis by addressing the following research questions:
What is the effect of 16 weeks of RT-CGM use, versus 16 weeks of CGM use, in patients with T1DM and IHA on
-
(primary objective:) time spent in euglycemia
-
(secondary objectives:)
-
(diabetes-specific) markers of QoL, covering diabetes-related emotional distress (PAID-5), fear of hypoglycemia (HFS-2), self-efficacy (CIDS), health status (EQ5D) and emotional well-being (WHO-5)
-
other glycemia variables, including HbA1c and time spent in hypo- and - hyperglycemia ranges
-
the incidence and duration of hypoglycemic episodes
-
changes in hypoglycemia awareness score according to Gold et al.,
- (tertiary objectives:)
-
measures of glucose variability
-
the autonomic nervous system balance
-
the duration of wear of the RT-CGM device
-
patients' therapy adjustments during the interventions
-
hypoglycemia awareness scores according to Clarke et al.
-
satisfaction with use of CGM
-
the number of contact moments not planned according to the study schedule
-
absence of work of patient (and spouse)
-
the global estimated costs of use of health care
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Real-time continuous glucose monitor 16 weeks use of a real-time continuous glucose monitor |
Device: Real-time continuous glucose monitor
Active Comparator: MiniMed Paradigm® Veo™-system Placebo Comparator: iPro™2 Continuous Glucose Monitor (masked)
Other Names:
|
| Placebo Comparator: Continuous glucose monitor 16 weeks use of a (blinded, retrospective) continuous glucose monitor |
Device: Real-time continuous glucose monitor
Active Comparator: MiniMed Paradigm® Veo™-system Placebo Comparator: iPro™2 Continuous Glucose Monitor (masked)
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Time spent in the euglycemic range [45 weeks]
The mean difference in time spent in the euglycemic range (interstitial glucose >3.9-<10.0 mmol/L), expressed as hours/day between the two 16-week intervention periods, i.e. RT-CGM versus masked CGM in patients with T1DM and IHA.
Secondary Outcome Measures
- Quality of life [45 weeks]
(diabetes-specific) markers of QoL, covering diabetes-related emotional distress (PAID-5), fear of hypoglycemia (HFS-2), self-efficacy (CIDS), health status (EQ5D) and emotional well-being (WHO-5)
- Glycemia variables [45 weeks]
Other glycemia variables, including HbA1c and time spent in hypo- and hyperglycemia ranges
- Hypoglycemic episodes [45 weeks]
The incidence and duration of hypoglycemic episodes
- Changes in hypoglycemia awareness score [45 weeks]
Changes in hypoglycemia awareness score according to Gold et al.
Other Outcome Measures
- Glucose variability [45 weeks]
RT-CGM derived measures of glucose variability, e.g. SD, MODD, CONGA
- ANS balance [45 weeks]
The autonomic nervous system balance
- Sensor wear duration [45 weeks]
The duration of wear of the RT-CGM device
- Therapy adjustments [45 weeks]
The therapy adjustments made by patients during the interventions
- Hypoglycemia awareness score [45 weeks]
Hypoglycemia awareness scores according to Clarke et al.
- RT-CGM satisfaction [45 weeks]
Satisfaction with use of CGM
Eligibility Criteria
Criteria
Inclusion Criteria:
-
T1DM, diagnosed according to ADA criteria regardless duration
-
Use of multiple daily injections of insulin (with a basal insulin injection and bolus injections) or continuous subcutaneous insulin infusion
-
Any HbA1c
-
Age between 18 and 70 years old (inclusive)
-
IHA according to the questionnaire by Gold et al.
-
Performing at least 3 SMBG/day or 21 SMBG/week
Exclusion Criteria:
-
Type 2 diabetes mellitus
-
History of (recent) major renal, liver, or (ischemic) heart disease (including cardiac conduction disorders)
-
Current untreated proliferative diabetic retinopathy
-
Current (treatment for) malignancy
-
Current use of non-selective beta-blockers
-
Current psychiatric disorders, including schizophrenia, bipolar disorder, anorexia nervosa or bulimia nervosa
-
Substance abuse or alcohol abuse (men >21 units/week, women >14 units/week)
-
Current pregnancy or intention to conceive
-
Current use of RT-CGM other than for short term (i.e. diagnostic use or use shorter than 3 consecutive months)
-
Hearing or vision impairment hindering perceiving of glucose display and alarms, or otherwise incapable of using a (RT-)CGM, in the opinion of the investigator
-
Poor commandment of the Dutch language or any (mental) disorder that precludes full understanding of the purpose and instructions of the study
-
Participation in another clinical study
-
Known or suspected allergy to trial product or related products
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | VU University Medical Center | Amsterdam | Noord-Holland | Netherlands | 1081 |
Sponsors and Collaborators
- Amsterdam UMC, location VUmc
- Eli Lilly and Company
Investigators
- Principal Investigator: Erik H Serné, MD PhD, Amsterdam UMC, location VUmc
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- DC2012INCONTROL01